Alicia C McDonald1, Manish Vira2, Vonn Walter1, Jing Shen3, Jay D Raman4, Martin G Sanda5, Dattatraya Patil5, Emanuela Taioli6,7. 1. Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania. 2. Smith Institute for Urology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York. 3. Gertrude H. Sergievsky Center, Columbia University Medical Center, New York, New York. 4. Department of Surgery, Division of Urology, Pennsylvania State Milton S. Hershey Medical Center, Hershey, Pennsylvania. 5. Department of Urology, Emory University School of Medicine, Atlanta, Georgia. 6. Department of Population Health Science and Policy, Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York. 7. Department of Thoracic Surgery, Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND: MicroRNAs (miRNAs or miR-) have been linked to factors associated with aggressive prostate cancer such as biochemical recurrence and metastasis. We investigated whether circulating miRNAs in plasma could be used as diagnostic biomarkers for more aggressive prostate cancer at prostate biopsy. METHODS: Men, aged 40 years and above, newly diagnosed with prostate cancer were categorized into two risk groups, low-grade (Gleason score, 6 or 7 [3 + 4] and serum prostate-specific antigen [PSA], <20 ng/mL) and high-grade (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) prostate cancers. The limma R package was used to compare the expression of miRNAs in plasma between the two risk groups, adjusting for age. RESULTS: There were 66 men, aged 46-86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. There were lower expressions of miR-28, miR-100, miR-942, and miR-28-3p, and higher expressions of miR-708, miR-1298, miR-886-3p, miR-374, miR-376c, miR-202, miR-128a, and miR-185 in high-grade compared to low-grade prostate cancer cases at biopsy, after adjusting for age (P < 0.05). These differences were no longer statistically significant after adjusting the P values for multiple comparisons. CONCLUSION: There was no circulating miRNA associated with high-grade prostate cancer at biopsy after adjusting for age and multiple comparisons. Nevertheless, relationships between these circulating miRNAs and high-grade prostate cancer were observed, which suggest them as promising prostate cancer biomarkers. Further investigation in a larger cohort may provide insight into their diagnostic potential for aggressive prostate cancer.
BACKGROUND: MicroRNAs (miRNAs or miR-) have been linked to factors associated with aggressive prostate cancer such as biochemical recurrence and metastasis. We investigated whether circulating miRNAs in plasma could be used as diagnostic biomarkers for more aggressive prostate cancer at prostate biopsy. METHODS:Men, aged 40 years and above, newly diagnosed with prostate cancer were categorized into two risk groups, low-grade (Gleason score, 6 or 7 [3 + 4] and serum prostate-specific antigen [PSA], <20 ng/mL) and high-grade (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) prostate cancers. The limma R package was used to compare the expression of miRNAs in plasma between the two risk groups, adjusting for age. RESULTS: There were 66 men, aged 46-86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. There were lower expressions of miR-28, miR-100, miR-942, and miR-28-3p, and higher expressions of miR-708, miR-1298, miR-886-3p, miR-374, miR-376c, miR-202, miR-128a, and miR-185 in high-grade compared to low-grade prostate cancer cases at biopsy, after adjusting for age (P < 0.05). These differences were no longer statistically significant after adjusting the P values for multiple comparisons. CONCLUSION: There was no circulating miRNA associated with high-grade prostate cancer at biopsy after adjusting for age and multiple comparisons. Nevertheless, relationships between these circulating miRNAs and high-grade prostate cancer were observed, which suggest them as promising prostate cancer biomarkers. Further investigation in a larger cohort may provide insight into their diagnostic potential for aggressive prostate cancer.
Authors: Hadley M Wood; Alwyn M Reuther; Timothy D Gilligan; Patrick A Kupelian; Charles S Modlin; Eric A Klein Journal: J Urol Date: 2007-08-14 Impact factor: 7.450
Authors: Jan C Brase; Marc Johannes; Thorsten Schlomm; Maria Fälth; Alexander Haese; Thomas Steuber; Tim Beissbarth; Ruprecht Kuner; Holger Sültmann Journal: Int J Cancer Date: 2011-02-01 Impact factor: 7.396
Authors: Qizhi Zheng; Sarah B Peskoe; Judit Ribas; Fatema Rafiqi; Tarana Kudrolli; Alan K Meeker; Angelo M De Marzo; Elizabeth A Platz; Shawn E Lupold Journal: Prostate Date: 2014-09-22 Impact factor: 4.104
Authors: Akira Watahiki; Yuwei Wang; James Morris; Kristopher Dennis; Helena M O'Dwyer; Martin Gleave; Peter W Gout; Yuzhuo Wang Journal: PLoS One Date: 2011-09-30 Impact factor: 3.240
Authors: Alicia C McDonald; Jay D Raman; Jing Shen; Jason Liao; Bhavyata Pandya; Manish A Vira Journal: Urol Oncol Date: 2019-08-14 Impact factor: 3.498
Authors: Monyse de Nóbrega; Mariana Bisarro Dos Reis; Érica Romão Pereira; Marilesia Ferreira de Souza; Ilce Mara de Syllos Cólus Journal: J Cancer Res Clin Oncol Date: 2022-08-04 Impact factor: 4.322